{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:06:47Z","timestamp":1790197607238,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.euo.2026.09.006","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:42:21Z","timestamp":1790196141000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing Pathological Response to Neoadjuvant Therapy in Kidney Cancer: Quality over Quantity?"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2194-4903","authenticated-orcid":false,"given":"James O.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C. Koen","family":"van der Mijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Bex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant D.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.09.006_b0005","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.annonc.2025.05.540","article-title":"What is required to deliver practice-changing neoadjuvant trials in kidney cancer? An International Neoadjuvant Kidney Cancer Consortium Delphi study","volume":"36","author":"Rossi","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.09.006_b0010","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1016\/S1470-2045(25)00345-6","article-title":"Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium","volume":"26","author":"Blackmur","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.09.006_b0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.annonc.2025.10.018","article-title":"Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort","volume":"37","author":"Deutsch","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.09.006_b0020","unstructured":"Croll BJ, Yahya HA, Fredette J, et al. Feasibility and characterization of immune-related pathologic response criteria in renal cell carcinoma. European urology oncology in press."},{"key":"10.1016\/j.euo.2026.09.006_b0025","doi-asserted-by":"crossref","first-page":"438.e11","DOI":"10.1016\/j.urolonc.2021.04.007","article-title":"Leibovich score is the optimal clinico-pathological system associated with recurrence of non-metastatic clear cell renal cell carcinoma","volume":"39","author":"Blackmur","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2026.09.006_b0030","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.ccell.2026.05.007","article-title":"Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma","volume":"44","author":"Vuong","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euo.2026.09.006_b0035","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1200\/JCO.2025.43.16_suppl.4509","article-title":"Exploratory analysis from NEOAVAX, a neoadjuvant trial of avelumab\/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy","volume":"43","author":"Bex","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.09.006_b0040","doi-asserted-by":"crossref","first-page":"S1636","DOI":"10.1016\/j.annonc.2025.09.112","article-title":"LBA95 neoadjuvant immunotherapy in locally advanced clear cell renal cell carcinoma at risk for recurrence or distant metastases: the randomized phase II NESCIO trial","volume":"36","author":"Burgers","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.09.006_b0045","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.euf.2025.06.012","article-title":"KIM-1 as a prognostic marker in renal cell carcinoma","volume":"11","author":"Steiner","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.09.006_b0050","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1200\/JCO.2026.44.16_suppl.4502","article-title":"ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial","volume":"44","author":"Choueiri","year":"2026","journal-title":"J Clin Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126002555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126002555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:42:23Z","timestamp":1790196143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126002555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":10,"alternative-id":["S2588931126002555"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.09.006","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing Pathological Response to Neoadjuvant Therapy in Kidney Cancer: Quality over Quantity?","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}